Skip to content

Deucravacitinib

Tyrosine Kinase 2 Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: BMS-986165, sotyktu

OnpEMA approvedFDA approvedPMDA approvedATC L04AF07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Deucravacitinib is an onp drug in the Tyrosine Kinase 2 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as Tyrosine Kinase 2 Inhibitors. DrugCentral lists 8 molecular targets, including TYK2, JAK1 and JAK3. Recorded indications include Erythrodermic psoriasis, Plaque psoriasis and Pustular psoriasis.

  • Approval status: onp (first approved 2022 by the FDA).
  • Drug class: Tyrosine Kinase 2 Inhibitor.
  • Mechanism of action: Tyrosine Kinase 2 Inhibitors.
  • Molecular targets: TYK2, JAK1, JAK3 and JAK2 (8 listed in DrugCentral).
  • Indications: Erythrodermic psoriasis, Plaque psoriasis and Pustular psoriasis.
  • ATC code: L04AF07 (Janus-associated kinase (JAK) inhibitors).
  • Molecular formula: C20H22N8O3; molecular weight 425.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

  • Erythrodermic psoriasis
  • Plaque psoriasis
  • Pustular psoriasis

Contraindications (2)

  • Active tuberculosis
  • Severe active infection

Mechanism & targets

Mechanism of action (MoA)Tyrosine Kinase 2 Inhibitors
Established pharmacologic classTyrosine Kinase 2 Inhibitor

Molecular targets (8)

TargetGeneActionActivity
Non-receptor tyrosine-protein kinase TYK2TYK2inhibitorIC50 9.70
Tyrosine-protein kinase JAK1JAK1inhibitorIC50 9.00
Tyrosine-protein kinase JAK3JAK3unknownIC50 8.52
Tyrosine-protein kinase JAK2JAK2unknownKd 8.00
Signal transducer and activator of transcription 1-alpha/betaSTAT1unknownIC50 7.47
Signal transducer and activator of transcription 3STAT3unknownIC50 7.05
Non-receptor tyrosine-protein kinase TYK2Tyk2unknownIC50 7.00
Bone morphogenetic protein receptor type-2BMPR2inhibitorIC50 6.71

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2023-03-24EMA—BRISTOL-MYERS SQUIBB PHARMA EEIG
2022-09-26PMDA—BRISTOL-MYERS SQUIBB K.K.
2022-09-09FDA—BRISTOL-MYERS SQUIBB

ATC classification

ATC codeTherapeutic hierarchy
L04AF07ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Acne613.6
Skin burning sensation291.3
Pruritus272.3
Erythema264.0
Mouth ulceration182.2
Rash114.2
Folliculitis97.0
Burning sensation75.0
Adverse event68.0
Therapy interrupted55.4
Drug ineffective43.1
Acne cystic42.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Deucravacitinib is on its molecule page.

Molecular formulaC20H22N8O3
Molecular weight425.47 g/mol
CAS number1609392-27-9
InChIKeyBZZKEPGENYLQSC-FIBGUPNXSA-N
PubChem CID134821691
[2H]C([2H])([2H])NC(=O)C1=C(NC2=C(OC)C(=CC=C2)C2=NN(C)C=N2)C=C(NC(=O)C2CC2)N=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Deucravacitinib used for?

DrugCentral lists the following indications for Deucravacitinib: Erythrodermic psoriasis, Plaque psoriasis and Pustular psoriasis.

How does Deucravacitinib work?

Deucravacitinib is classified as Tyrosine Kinase 2 Inhibitors; its molecular targets in DrugCentral include TYK2 (inhibitor), JAK1 (inhibitor), JAK3 and JAK2.

When was Deucravacitinib first approved?

Deucravacitinib was first approved by the FDA in 2022.

What drug class does Deucravacitinib belong to?

Deucravacitinib is in the Tyrosine Kinase 2 Inhibitor class.

What is the chemical formula of Deucravacitinib?

Deucravacitinib has the molecular formula C20H22N8O3 and a molecular weight of 425.47 g/mol.

Browse: all drugs starting with D · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2022-09-09
AgencyFDA
Targets8
Indications3
FormulaC20H22N8O3
DrugCentral ID5677
Interactive profile